Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial

Research output: Contribution to journalJournal articlepeer-review

Standard

Neonatal BCG vaccination and atopic dermatitis before 13 months of age : A randomized clinical trial. / Thøstesen, L.M.; Kjærgaard, J.; Pihl, G.T.; Birk, N.M.; Nissen, T.N.; Aaby, P.; Jensen, A.K.G.; Olesen, A.W.; Stensballe, L.G.; Jeppesen, D. L.; Benn, C S; Kofoed, P.-E.

In: Allergy, Vol. 73, No. 2, 2018, p. 498-504.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Thøstesen, LM, Kjærgaard, J, Pihl, GT, Birk, NM, Nissen, TN, Aaby, P, Jensen, AKG, Olesen, AW, Stensballe, LG, Jeppesen, DL, Benn, CS & Kofoed, P-E 2018, 'Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial', Allergy, vol. 73, no. 2, pp. 498-504. https://doi.org/10.1111/all.13314

APA

Thøstesen, L. M., Kjærgaard, J., Pihl, G. T., Birk, N. M., Nissen, T. N., Aaby, P., Jensen, A. K. G., Olesen, A. W., Stensballe, L. G., Jeppesen, D. L., Benn, C. S., & Kofoed, P-E. (2018). Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial. Allergy, 73(2), 498-504. https://doi.org/10.1111/all.13314

Vancouver

Thøstesen LM, Kjærgaard J, Pihl GT, Birk NM, Nissen TN, Aaby P et al. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial. Allergy. 2018;73(2):498-504. https://doi.org/10.1111/all.13314

Author

Thøstesen, L.M. ; Kjærgaard, J. ; Pihl, G.T. ; Birk, N.M. ; Nissen, T.N. ; Aaby, P. ; Jensen, A.K.G. ; Olesen, A.W. ; Stensballe, L.G. ; Jeppesen, D. L. ; Benn, C S ; Kofoed, P.-E. / Neonatal BCG vaccination and atopic dermatitis before 13 months of age : A randomized clinical trial. In: Allergy. 2018 ; Vol. 73, No. 2. pp. 498-504.

Bibtex

@article{f8eef15510864ffe880d6e8fc5942c56,
title = "Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial",
abstract = "BACKGROUND: Studies have suggested that Bacillus Calmette-Gu{\'e}rin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).",
author = "L.M. Th{\o}stesen and J. Kj{\ae}rgaard and G.T. Pihl and N.M. Birk and T.N. Nissen and P. Aaby and A.K.G. Jensen and A.W. Olesen and L.G. Stensballe and Jeppesen, {D. L.} and Benn, {C S} and P.-E. Kofoed",
note = "{\textcopyright} 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",
year = "2018",
doi = "10.1111/all.13314",
language = "English",
volume = "73",
pages = "498--504",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Online",
number = "2",

}

RIS

TY - JOUR

T1 - Neonatal BCG vaccination and atopic dermatitis before 13 months of age

T2 - A randomized clinical trial

AU - Thøstesen, L.M.

AU - Kjærgaard, J.

AU - Pihl, G.T.

AU - Birk, N.M.

AU - Nissen, T.N.

AU - Aaby, P.

AU - Jensen, A.K.G.

AU - Olesen, A.W.

AU - Stensballe, L.G.

AU - Jeppesen, D. L.

AU - Benn, C S

AU - Kofoed, P.-E.

N1 - © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

AB - BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

U2 - 10.1111/all.13314

DO - 10.1111/all.13314

M3 - Journal article

C2 - 28929567

VL - 73

SP - 498

EP - 504

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 2

ER -

ID: 197811819